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per QALY gained for improved diabetes management for the
program effect lasting for 1 year was $19,573. CONLCUSIONS:
This diabetes management program improved clinical outcomes
for study participants. The results from the cost-effectiveness
analysis reveal that the multifaceted program aimed at increas-
ing the continuity of care for patients with diabetes represents
good value for money.
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OBJECTIVES: Combination therapy, with either repaglinide or
nateglinide in addition to metformin, is typically initiated in
patients with type 2 diabetes unable to achieve glycemic control
with monotherapy. The efﬁcacy and safety of treatment with
these two therapies in combination with metformin has been
evaluated in a head-to-head clinical trial over 16 weeks in type
2 diabetes patients with an inadequate response to sulphonylurea
or metformin alone. The study demonstrated that after 16 weeks
of therapy, patients treated with Repag+Met had lower HbA1c
levels than those treated with Nateg+Met (-1.28% vs -0.67%).
METHODS: A published and peer-reviewed model for type 2
diabetes was used in the analysis to project the impact of treat-
ment with repaglinide and nateglinide, on long-term outcomes
including life expectancy, quality-adjusted life expectancy and
lifetime costs in the Finnish setting. Annual medication costs in
each treatment arm were calculated using the median end of trial
doses. Direct medical costs of treating diabetes-related compli-
cations used in the analysis were collected from published liter-
ature. Outcomes were discounted at 5% annually, in line with
Finnish recommendations. RESULTS: Repaglinide was projected
to increase life expectancy (0.12 years) and quality-adjusted life
expectancy (0.11 years) compared to nateglinide. Lifetime costs
in patients treated with repaglinide were projected to be €2627
lower than nateglinide. Improvements in long-term outcomes
were attributed to a delayed onset of diabetes-related complica-
tions, particularly those associated with retinopathy and
nephropathy. CONCLUSIONS: In combination with metformin,
repaglinide was projected to be dominant to nateglinide, with
improvements in LE, QALE and costs, in the Finnish setting.
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OBJECTIVE: To present the structure and design of a Markov
model intended to determine the cost-effectiveness of the
FreeStyle Navigator™ continuous glucose monitoring system
(NAV) which provides real-time, glucose level readings while
also measuring and displaying the rate and direction of glucose
level changes. The model compares self-monitoring of blood
glucose (SMBG) to the use of NAV in patients with insulin-
requiring Type 1 diabetes who are either trained or untrained in
proper glycemic management, highlighting the ability of each
monitoring device to predict hypoglycemia and hyperglycemia.
METHODS: The model was constructed using probability and
utility values derived from published clinical literature, and sim-
ulates distributions for each monitoring approach into one of ten
diabetic health states. Treatment costs are based on retail prices
and current Medicare reimbursement rates. Cost and effective-
ness values are accumulated monthly over a 36-month period,
yielding incremental cost-effectiveness ratios (ICER) in dollars
per quality-adjusted life month ($/QALM). RESULTS: Model
analysis demonstrates that the use of NAV by a patient trained
in diabetes management is more cost-effective than SMBG.
Although NAV has a higher overall cost of treatment as com-
pared to SMBG ($12,831 v. $8044), it also has a greater effec-
tiveness (57.8QALM v. 44.3QALM), resulting in an ICER of
$355/QALM ($4,269/QALY) for NAV over SMBG. The glucose
level rate of change and trend information provided by the
FreeStyle Navigator™ has been shown to allow appropriately
trained patients to improve upon decisions regarding self-
treatment to better prevent hypo- and hyperglycemic episodes;
resulting in a lower overall treatment cost and higher overall
effectiveness as compared to the use of NAV by an untrained
patient. CONCLUSION: Based on current performance attrib-
utes, a device such as NAV would be more cost-effective than
traditional glucose monitoring options, meeting the willingness-
to-pay threshold of $50,000/QALY commonly used by payers
for the adoption of new technology.
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OBJECTIVES: Clinical evidence suggests that achieving recom-
mended lipid levels reduces the likelihood of CHD events and
mortality. The beneﬁts of statins on LDL-Cholesterol reduction
have been well established, however, improving other lipid para-
meters can contribute to further CHD risk reduction, as low
HDL-C has been shown to be a strong independent risk factor
for CHD. This cost-effectiveness model was developed to deter-
mine the incremental cost of meeting additional recommended
lipid levels when fenoﬁbrate is added to statin therapy in dia-
betic or metabolic syndrome (MS) patients. METHODS: A sim-
ulation model was designed to predict changes in lipid levels
[HDL-C, LDL-C, triglycerides (TG), total cholesterol (TC)] and
associated drug costs based on Wholesale Acquisition Costs over
the course of 1 year. Lipid targets were based on NCEP-ATP III.
A hypothetical cohort of 1000 was modeled for each disease with
abnormal lipid levels based on NHANES data. Comparators for
diabetic patients were atorvastatin and atorvastatin/fenoﬁbrate
combination. Lipid reductions for diabetic patients were based
on the study by Athyros et al. 2002. Comparators for MS were
simvastatin and simvastatin/fenoﬁbrate combination, and lipid
reductions for MS patients were based on the SAFARI trial.
RESULTS: In a cohort of 1000, adding fenoﬁbrate to atorvas-
tatin resulted in 547 more diabetic patients reaching TG targets
and 483 more reaching HDL-C targets. For MS, adding fenoﬁ-
brate to simvastatin resulted in 549 more patients reaching TG
targets, and 288 more reaching HDL targets. 555 more patients
in the diabetic group achieved at least 3 targets while 525 more
MS patients reached at least 3 targets. The 1 year cost per addi-
tional patient reaching three targets was $1848 for diabetics and
